[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most appropriate management strategy for this patient, I need to analyze his clinical presentation and current condition.\n\nThe patient has:\n- Ischemic cardiomyopathy with severely reduced LVEF (20%)\n- NYHA class III symptoms despite guideline-directed therapy\n- Signs of right heart failure (elevated JVP, abdominal swelling)\n- Severe functional tricuspid regurgitation with right ventricular dysfunction\n- Hypotension (BP 88/54 mm Hg)\n- Non-revascularizable coronary disease\n- Not a heart transplant candidate\n\nLet's evaluate each option:\n\nA. Surgical tricuspid valve replacement: High risk given his severe biventricular failure and hypotension.\n\nB. Catheter-based edge-to-edge tricuspid valve repair: Could address the tricuspid regurgitation with lower procedural risk than surgery, potentially improving right heart function and symptoms.\n\nC. Isolated LV assist device implantation: While this would support left ventricular function, the patient has significant right heart failure which would likely lead to right ventricular failure post-LVAD.\n\nD. Upgrade to CRT-D with AV node ablation: No mention of atrial fibrillation or ventricular dyssynchrony that would benefit from this approach.\n\nE. Intensification of neurohormonal blockade: Unlikely to be tolerated given his hypotension, and unlikely to significantly improve his severe tricuspid regurgitation.\n\nGiven the severe functional tricuspid regurgitation with right heart failure symptoms, and considering his high surgical risk, the catheter-based approach would be most appropriate.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the patient's presentation and diagnostic findings for pulmonary hypertension.\n\nThe patient has:\n- Severe pulmonary hypertension (PASP 80 mmHg, mPAP 52 mmHg)\n- Normal PCWP (9 mmHg), indicating pre-capillary PH\n- Elevated PVR (10 Wood units)\n- Normal V/Q scan (ruling out chronic thromboembolic PH)\n- Family history of sudden death and pending genetic testing (suggesting possible heritable PAH)\n- Acute vasoreactivity testing shows some response but not meeting criteria for a positive response\n\nFor a positive acute vasoreactivity test, we typically look for:\n- Decrease in mPAP by ≥10 mmHg to reach an absolute value ≤40 mmHg\n- With increased or unchanged cardiac output\n\nThis patient's response (mPAP from 52 to 42 mmHg) shows some response but doesn't fully meet criteria for a true vasoreactive patient who would benefit from CCB therapy.\n\nFor non-vasoreactive PAH or partially responsive PAH with this severity (functional class likely II-III based on symptoms, with preserved RV function but reduced CI), initial combination therapy with an endothelin receptor antagonist and a PDE-5 inhibitor is recommended.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most appropriate antiepileptic monotherapy for this patient, I need to consider:\n\n1. The seizure type: The patient has generalized tonic-clonic seizures preceded by myoclonic jerks, with EEG showing generalized spike-and-wave discharges and photoparoxysmal response - consistent with genetic/idiopathic generalized epilepsy.\n\n2. Patient-specific factors:\n   - 27-year-old male\n   - Planning conception with partner\n   - Wants to avoid cognitive side effects\n   - Works as a software engineer (cognitive demands)\n   - Social drinker\n\nFor genetic generalized epilepsy with both myoclonic and generalized tonic-clonic seizures:\n\n- Valproate is highly effective but has teratogenic risks and may affect sperm parameters.\n- Levetiracetam is effective for both myoclonic and generalized tonic-clonic seizures with minimal cognitive effects and no significant reproductive risks.\n- Carbamazepine can worsen myoclonic seizures and is not indicated for genetic generalized epilepsy.\n- Lamotrigine is effective for generalized tonic-clonic seizures but may be less effective for myoclonic seizures.\n- Topiramate can cause significant cognitive side effects.\n\nGiven the patient's desire to avoid cognitive side effects and future conception plans, levetiracetam offers the best balance of efficacy for both seizure types with minimal cognitive impact and reproductive safety.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To determine the most likely diagnosis, I'll analyze the key findings in this case:\n\n1. Patient has poorly controlled type 2 diabetes for 10 years\n2. Experiencing hypoglycemic episodes (glucose 38 mg/dL) with autonomic symptoms\n3. Takes metformin and basal insulin at night\n4. During hypoglycemia (42 mg/dL):\n   - Insulin level is 6 μU/mL (within normal range)\n   - C-peptide is low at 0.1 ng/mL\n   - Beta-hydroxybutyrate undetectable\n   - Negative sulfonylurea/meglitinide screen\n5. Normal pancreatic CT\n\nThe critical finding is the combination of detectable insulin with suppressed C-peptide during hypoglycemia. C-peptide is produced in equimolar amounts with endogenous insulin, so this discrepancy strongly suggests exogenous insulin administration. When someone injects insulin, blood insulin levels rise but C-peptide remains low because the pancreas isn't producing the insulin.\n\nThe normal CT rules out insulinoma, and the normal insulin level with low C-peptide is inconsistent with non-islet cell tumors or autoimmune conditions. There's no mention of bariatric surgery in the history.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to consider the management of cardiac arrest due to massive pulmonary embolism.\n\nThe patient has a confirmed massive PE with hemodynamic compromise that progressed to cardiac arrest with PEA. After 10 minutes of standard ACLS without ROSC, specific interventions targeting the PE are needed.\n\nOption A (full-dose systemic alteplase during CPR) is appropriate in this scenario. For cardiac arrest due to suspected or confirmed PE, guidelines support administering thrombolytic therapy during CPR. Full-dose systemic thrombolysis (100 mg alteplase) can be given as a bolus during ongoing CPR, as it may dissolve the clot and potentially achieve ROSC.\n\nOption B (VA-ECMO followed by catheter thrombectomy) would be ideal but requires specialized equipment and personnel that may not be immediately available during an active cardiac arrest.\n\nOption C (half-dose alteplase) is not standard practice for PE-related cardiac arrest.\n\nOption D (termination) is premature given the potentially reversible cause of arrest.\n\nOption E (emergency surgical embolectomy without ECMO) would be extremely high-risk without cardiopulmonary support.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with features of an inflammatory myopathy with interstitial lung disease. The clinical picture shows:\n- Proximal muscle weakness\n- Gottron papules (characteristic of dermatomyositis)\n- \"Mechanic's hands\" rash\n- Mildly elevated CK\n- Significant interstitial lung disease on HRCT and PFTs\n- Positive ANA\n\nAmong the antibodies listed:\n\nA. Anti-Jo-1 is associated with antisynthetase syndrome and can cause ILD, but typically with higher CK levels.\n\nB. Anti-Mi-2 is associated with classic dermatomyositis but has a relatively good prognosis and less severe ILD.\n\nC. Anti-MDA5 (melanoma differentiation-associated gene 5) is strongly associated with clinically amyopathic dermatomyositis and rapidly progressive ILD with high mortality. This patient's presentation with mild muscle involvement, characteristic skin findings, and significant lung disease fits this profile.\n\nD. Anti-SRP is associated with necrotizing myopathy with very high CK levels but less ILD.\n\nE. Anti-TIF1-γ is associated with dermatomyositis and increased cancer risk but not severe ILD.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the patient's clinical presentation and the evidence-based approaches for managing chronic hypercapnic respiratory failure in COPD.\n\nThe patient has:\n- Severe COPD (FEV1 35% predicted)\n- Chronic hypercapnia (PaCO2 58 mm Hg) with compensated respiratory acidosis\n- Recent exacerbation requiring NIV\n- Ongoing symptoms (daytime somnolence, morning headaches)\n- Nocturnal hypoventilation with desaturations\n- Already on oxygen therapy and adherent to standard COPD treatments\n\nOption A (Increasing oxygen): While oxygen therapy is beneficial in hypoxemic COPD, increasing oxygen to maintain PaO2 >80 mmHg could worsen hypercapnia in this patient who already has elevated CO2 levels.\n\nOption B (Nocturnal NIV): For patients with severe COPD and chronic hypercapnia, especially after an exacerbation requiring acute NIV, evidence from trials like the HOT-HMV study shows that home nocturnal NIV targeting normalization of PaCO2 can reduce mortality and rehospitalization.\n\nOption C (Chronic oral prednisone): Long-term systemic corticosteroids have significant side effects and are not recommended for stable COPD management.\n\nOption D (Acetazolamide): While it can stimulate ventilation, there's insufficient evidence for its routine use in COPD to improve mortality.\n\nOption E (High-flow nasal cannula): While emerging as a therapy, it has less evidence for mortality benefit in chronic hypercapnic COPD compared to NIV.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the patient's presentation and current medication regimen.\n\nThe patient has:\n- History of MI and paroxysmal atrial fibrillation\n- Currently taking apixaban 5 mg BID (appropriate anticoagulation for atrial fibrillation)\n- Experienced a branch retinal artery occlusion (BRAO)\n- Normal MRI and no large vessel occlusion or significant carotid stenosis\n\nThe key consideration is whether his current anticoagulation regimen is appropriate given this embolic event.\n\nOption A (adding aspirin) would increase bleeding risk without clear benefit, especially since he's already on appropriate anticoagulation.\n\nOption B (switching to warfarin with higher INR) isn't supported by evidence for this scenario and may increase bleeding risk.\n\nOption C (continuing current apixaban) recognizes that the patient is already on appropriate anticoagulation for his atrial fibrillation. Despite the BRAO, there's no evidence that changing his regimen would provide additional benefit.\n\nOption D (temporarily increasing apixaban dose) isn't supported by evidence and exceeds approved dosing.\n\nOption E (switching to DAPT) would be inappropriate for a patient with atrial fibrillation who needs anticoagulation.\n\nSince the patient is already on appropriate anticoagulation for his atrial fibrillation and has had good adherence, the most appropriate management is to continue the current regimen.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to analyze the case of a 46-year-old man with an acute Stanford type B aortic dissection.\n\nKey findings:\n- Stanford type B dissection (starts distal to left subclavian artery)\n- Left renal artery involvement with mild renal dysfunction (creatinine 1.4 mg/dL from baseline 1.0)\n- No signs of rupture, pericardial effusion, limb ischemia, mesenteric ischemia\n- No refractory pain after initial treatment\n- BP now controlled at 115/70 mmHg\n\nThis is an uncomplicated type B aortic dissection with mild renal involvement. The patient has responded to initial medical therapy with good blood pressure control and no evidence of malperfusion syndrome or refractory pain.\n\nFor uncomplicated type B dissections, the standard of care is medical management with blood pressure control and close follow-up imaging. Immediate intervention (surgical or endovascular) is generally reserved for complicated cases with evidence of rupture, malperfusion syndromes, refractory pain, or uncontrollable hypertension.\n\nWhile there is mild renal involvement, the kidney is still perfused, and the creatinine elevation is modest. This alone does not warrant immediate intervention if the patient is otherwise stable on medical therapy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical presentation and determine the most appropriate pharmacologic intervention.\n\nThe patient presents with:\n- Hyperthermia (40.1°C)\n- Tachycardia (HR 146/min)\n- Hypertension (BP 178/104 mm Hg)\n- Tachypnea (RR 28/min)\n- Mydriasis, diaphoresis, agitation, tremor\n- Hyperreflexia and inducible clonus\n- Positive UDS for amphetamines\n- No muscle rigidity\n- Normal CK levels\n- No response to high-dose benzodiazepines\n\nThis presentation is most consistent with serotonin syndrome, likely from a serotonergic research chemical with amphetamine-like properties. The key findings supporting this diagnosis are hyperthermia, autonomic instability, and neuromuscular abnormalities (hyperreflexia, clonus) without significant muscle rigidity.\n\nFor severe serotonin syndrome unresponsive to benzodiazepines:\n- Cyproheptadine (a 5-HT2A antagonist) is the specific pharmacologic treatment\n- Dantrolene is used for malignant hyperthermia and sometimes for neuroleptic malignant syndrome\n- Bromocriptine is used for neuroleptic malignant syndrome\n- Nitroprusside alone would only address hypertension without treating the underlying syndrome\n- Dexmedetomidine may help with agitation but is not specific therapy for serotonin syndrome\n\nThe answer is (B)"}]